لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل.

المؤلفون: Lesokhin AM; Division of Hematology and Oncology, Memorial Sloan Kettering Cancer Center/Weill Cornell Medical College, New York City, NY, USA. lesokhia@mskcc.org., Tomasson MH; Department of Internal Medicine, University of Iowa, Iowa City, IA, USA., Arnulf B; Hôpital Saint-Louis, Paris, France., Bahlis NJ; Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, Alberta, Canada., Miles Prince H; Epworth Healthcare and University of Melbourne, Melbourne, Victoria, Australia., Niesvizky R; Weill Cornell Medical College/New York Presbyterian Hospital, New York City, NY, USA., Rodrίguez-Otero P; Clinica Universidad de Navarra, Madrid, Spain., Martinez-Lopez J; Hospital Universitario 12 de Octubre, Madrid, Spain., Koehne G; Miami Cancer Institute, Miami, FL, USA., Touzeau C; University Hospital of Nantes, Nantes, France., Jethava Y; Indiana Blood & Marrow Transplant, Indianapolis, IN, USA., Quach H; University of Melbourne, St. Vincent's Hospital Melbourne, Melbourne, Victoria, Australia., Depaus J; Université Catholique de Louvain, CHU UCL Namur, Yvoir, Belgium., Yokoyama H; Tohoku University Graduate School of Medicine, Sendai, Japan., Gabayan AE; Beverly Hills Cancer Center, Beverly Hills, CA, USA., Stevens DA; Norton Cancer Center, Louisville, KY, USA., Nooka AK; Winship Cancer Institute, Atlanta, GA, USA., Manier S; Lille University Hospital and INSERM UMR-S1277, Lille, France., Raje N; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA., Iida S; Department of Hematology & Oncology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan., Raab MS; Heidelberg Myeloma Center, Department of Hematology/Oncology, Heidelberg University Hospital, Heidelberg, Germany., Searle E; The Christie Hospital, The University of Manchester, Manchester, UK., Leip E; Pfizer Inc, Cambridge, MA, USA., Sullivan ST; Pfizer Inc, Cambridge, MA, USA., Conte U; Pfizer Inc, New York, NY, USA., Elmeliegy M; Pfizer Inc, San Diego, CA, USA., Czibere A; Pfizer Inc, New York, NY, USA., Viqueira A; Pfizer SLU, Madrid, Spain., Mohty M; Sorbonne University, Hôpital Saint-Antoine, and INSERM UMRs938, Paris, France.

المصدر: Nature medicine [Nat Med] 2023 Sep; Vol. 29 (9), pp. 2259-2267. Date of Electronic Publication: 2023 Aug 15.

نوع المنشور: Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Nature Publishing Company Country of Publication: United States NLM ID: 9502015 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1546-170X (Electronic) Linking ISSN: 10788956 NLM ISO Abbreviation: Nat Med Subsets: MEDLINE

مواضيع طبية MeSH: Multiple Myeloma*/drug therapy, Humans ; B-Cell Maturation Antigen ; Progression-Free Survival ; Remission Induction

المؤلفون: Beatty GL; Department of Medicine, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA gregory.beatty@uphs.upenn.edu., Shahda S; Hematology/Oncology, Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, USA., Beck T; Hematology/Oncology, Highlands Oncology Group, Fayetteville, Arkansas, USA., Uppal N; Department of Medicine, NYU Langone Arena Oncology, Lake Success, New York, USA., Cohen SJ; Medical Oncology and Hematology Division, Jefferson Health/Abington Memorial Hospital, Abington, Pennsylvania, USA., Donehower R; Division of Medical Oncology, The Johns Hopkins Medical Institutions, Baltimore, Maryland, USA., Gabayan AE; Hematology/Oncology, Beverly Hills Cancer Center, Beverly Hills, California, USA., Assad A; Oncology Drug Development, Incyte Corporation, Wilmington, Delaware, USA., Switzky J; Clinical Research, Incyte Corporation, Wilmington, Delaware, USA., Zhen H; Biostatistics, Incyte Corporation, Wilmington, Delaware, USA., Von Hoff DD; Molecular Medicine Division, Translational Genomics Research Institute (TGen), Scottsdale, Arizona, USA.; Oncology, HonorHealth Clinical Research Institute, Phoenix, Arizona, USA.

المصدر: The oncologist [Oncologist] 2019 Jan; Vol. 24 (1), pp. 14-e10. Date of Electronic Publication: 2018 Aug 16.

نوع المنشور: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Oxford University Press Country of Publication: England NLM ID: 9607837 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1549-490X (Electronic) Linking ISSN: 10837159 NLM ISO Abbreviation: Oncologist Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Combined Chemotherapy Protocols/*therapeutic use , Deoxycytidine/*analogs & derivatives , Janus Kinase 1/*antagonists & inhibitors , Neoplasms/*drug therapy, Antineoplastic Combined Chemotherapy Protocols/pharmacology ; Deoxycytidine/pharmacology ; Deoxycytidine/therapeutic use ; Female ; Humans ; Male ; Neoplasms/pathology ; Treatment Outcome ; Gemcitabine

المؤلفون: Jagannath S; St. Vincent's Comprehensive Cancer Center, New York, NY 10011, USA. sjagannath@aptiumoncology.com, Durie BG, Wolf JL, Camacho ES, Irwin D, Lutzky J, McKinley M, Potts P, Gabayan AE, Mazumder A, Crowley J, Vescio R

المصدر: British journal of haematology [Br J Haematol] 2009 Sep; Vol. 146 (6), pp. 619-26. Date of Electronic Publication: 2009 Jul 20.

نوع المنشور: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 0372544 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1365-2141 (Electronic) Linking ISSN: 00071048 NLM ISO Abbreviation: Br J Haematol Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Agents/*therapeutic use , Boronic Acids/*therapeutic use , Dexamethasone/*therapeutic use , Multiple Myeloma/*drug therapy , Pyrazines/*therapeutic use, Adult ; Aged ; Aged, 80 and over ; Antineoplastic Agents/adverse effects ; Boronic Acids/adverse effects ; Bortezomib ; Dexamethasone/adverse effects ; Drug Therapy, Combination ; Female ; Follow-Up Studies ; Humans ; Male ; Middle Aged ; Multiple Myeloma/mortality ; Pyrazines/adverse effects ; Stem Cell Transplantation ; Survival Analysis ; Treatment Outcome